Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Lymphoma
Non-Hodgkin Lymphoma
18 Years and older, Male and Female
M-2023-401 (primary)
NCI-2024-03935
Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously
received zamtocabtagene autoleucel, known as MB-CART2019.1.
Objectives
This is a non-therapeutic study design. After successful screening, subjects will be
monitored for potential gene therapy-related adverse events for up to 15 years post
MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed
adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed
for long term efficacy as well as CAR-T persistence.
Eligibility
- Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
- Provided written informed consent to participate in this study.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.